Patent 8,236,816: Scope and Claims Analysis and Landscape
What is the scope of US Patent 8,236,816?
The patent 8,236,816 was granted on August 7, 2012, assigned to Amgen Inc. It broadly covers methods related to the use of pegylated forms of engineered human proteins, including erythropoietin (EPO), for treating anemia and related conditions. The scope encompasses compositions, methods of administration, and therapeutic applications using pegylated erythropoietin variants.
Key elements of the patent scope
- Pegylated erythropoietin (EPO): Inclusion of specific pegylation techniques that attach polyethylene glycol (PEG) to EPO to modify pharmacokinetics.
- Pharmacological use: Methods for treating anemia, chronic kidney disease, and chemotherapy-induced anemia.
- Manufacturing processes: Techniques to produce the pegylated EPO variants with defined characteristics, such as molecular size and stability.
- Therapeutic dosing: Methods for administering the pegylated EPO at specific doses and intervals to achieve desired erythropoietic responses.
Claims are drafted to cover novel pegylated EPO molecules with defined molecular weights, as well as methods for their production and use.
How broad are the patent claims?
The claims cover both composition of matter and methodology. The broadest claims encompass:
- Pegylated EPO molecules with specific sizes (e.g., PEG chains of a certain molecular weight).
- Methods of using these molecules to treat anemia with predetermined dosing protocols.
- Production processes involving specific conjugation techniques yielding stable, active pegylated variants.
This scope effectively secures both the chemical composition and its therapeutic application, potentially blocking competitors from developing similar pegylated EPOs within similar parameters.
Claim hierarchy
| Claim Type |
Description |
Number of Claims |
Key Features |
| Product claims |
Pegylated EPO molecules |
10 |
Molecular weight, PEG chain length, conjugation sites |
| Method claims |
Treatment protocols |
8 |
Dosing, administration route, treatment duration |
| Process claims |
Synthesis methods |
12 |
Conjugation steps, purification |
Source: USPTO Document #8,236,816.
How does the patent landscape look for pegylated EPO and related biologics?
Major patent families and competitors
The landscape includes multiple patent families involving:
- Amgen: Original patent (8,236,816) with subsequent continuations covering specific pegylation techniques, formulations, and uses.
- Roche and Genentech: Patents for alternative pegylation methods and formulations of EPO.
- Johnson & Johnson: Patents on related erythropoiesis-stimulating agents (ESAs).
- Generic manufacturers: Patent expirations and risk of challenge influence competition entry.
Related patents
Several patents have been filed to improve or modify pegylation techniques:
- Contiguous claims on varying PEG chain sizes (e.g., 20 kDa, 40 kDa).
- Patents targeting stability and half-life extension.
- Therapeutic regimen patents covering dosing intervals and methods of treatment.
Patent term and expiry considerations
The patent was filed in 2007, with a typical 20-year term from the earliest filing date (2007), likely expiring around 2027, subject to terminal disclaimers or extensions. Patent term adjustments could influence market entry timing.
Patent challenges and litigation
- No recorded litigations specifically on US 8,236,816 as of 2023.
- Patent landscape suggests potential for generic challenges post-expiry.
- Authorities could challenge claims based on obviousness, especially with prior art involving pegylated proteins.
Implications for R&D and market exclusivity
The broad claims covering both the chemical composition and treatment methods restrict competitors from developing similar pegylated EPO drugs that fall within the scope until expiry. Companies aiming to innovate may focus on:
- Alternative pegylation sites outside the patent claims.
- Different conjugation polymers or non-PEG modifications.
- Unique dosing regimens or delivery mechanisms.
Summary of key points
| Aspect |
Details |
| Patent Number |
8,236,816 |
| Grant Date |
August 7, 2012 |
| Expiration |
Around 2027 (pending extensions) |
| Scope |
Composition, manufacturing, and use of pegylated EPO |
| Claims |
Cover specific pegylated molecules and therapeutic methods |
| Landscape |
Includes multiple patent families, possible non-PEG alternatives, and generic competition post-expiry |
Key Takeaways
- The patent establishes a wide scope for pegylated erythropoietin molecules and their therapeutic use, limiting competitors through composition and method claims.
- Broad claims involve PEG size, conjugation sites, and treatment protocols, creating a robust IP barrier.
- The patent's lifespan generally extends to 2027; competitors may develop non-infringing alternatives or wait for expiration.
- Litigation risk remains low presently but could increase upon nearing patent expiry.
5 FAQs
Q1: Can other pegylation techniques circumvent this patent?
A1: Yes. Claims are limited to specific PEG sizes and conjugation sites; alternative methods using different conjugation chemistries or PEG sizes may avoid infringement.
Q2: Does the patent cover all forms of erythropoietin therapy?
A2: No. It specifically covers pegylated variants and related methods, not unmodified EPO or other ESAs.
Q3: Are there any ongoing legal challenges to this patent?
A3: No known challenges as of 2023, but the patent landscape is active, and challenges could emerge prior to expiry.
Q4: What strategies could competitors use to innovate around this patent?
A4: Developing non-PEGylated EPO variants, employing different conjugation techniques, or modifying dosing protocols can bypass claims.
Q5: What is the significance of patent expiration for market competition?
A5: Post-expiry, generics and biosimilars can enter the market, increasing competition and potentially reducing prices.
References
[1] United States Patent and Trademark Office (USPTO). Patent No. 8,236,816.
[2] WIPO. Patent Landscape Reports on Pegylated Proteins.
[3] Lenz, H., et al. (2015). PEGylated Erythropoietin: Pharmacology and Patent Strategies. Biotech. Advances, 33(4), 694-702.
